Rosen Law Firm Urges Tandem Diabetes Care Investors to Explore Securities Class‑Action Options

Rosen Law Firm has announced that it is investigating possible securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). The firm alleges that Tandem may have provided materially misleading business information to the public, triggering potential investor harm. The investigation stems from a company disclosure on August 7, 2025 — before the trading day opened — in which Tandem issued a “Voluntary Medical Device Correction” for certain t:slim X2 insulin pumps. The recall was said to address a “speaker‑related issue” that could lead to an error causing the pump to cease insulin delivery. Following that announcement, Tandem’s share price dropped 19.9%, closing at $11.52 per share on August 7, 2025. Investors who purchased Tandem securities and suffered losses may be eligible for compensation — with no out-of-pocket costs under a contingency‑fee arrangement. To participate in the prospective class action, Rosen Law Firm asks interested shareholders to submit a form online or contact attorney Phillip Kim by phone or email. #TandemDiabetesCare #SecuritiesFraud #InvestorAlert #ClassAction #SlimScan #GrowthStocks #CANSLIM